Parnell Pharmaceuticals Holdings Revenue 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings revenue from 2014 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Parnell Pharmaceuticals Holdings Annual Revenue
(Millions of US $) |
| 2021 |
$27 |
| 2020 |
$17 |
| 2019 |
$20 |
| 2018 |
$23 |
| 2017 |
$15 |
| 2016 |
$15 |
| 2015 |
$15 |
| 2014 |
$8 |
| 2014 |
$0 |
| 2013 |
$9 |
| 2013 |
$0 |
| 2012 |
$10 |
Parnell Pharmaceuticals Holdings Quarterly Revenue
(Millions of US $) |
| 2018-06-30 |
|
| 2018-03-31 |
$4 |
| 2017-12-31 |
|
| 2016-12-31 |
$4 |
| 2016-09-30 |
$4 |
| 2015-12-31 |
$3 |
| 2015-09-30 |
$3 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
|
| 2014-03-31 |
$1 |
| 2013-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
